Successful Treatment of Crizotinib-Associated Severe Hepatotoxicity in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
- Author:
Joon JIN
1
;
Seo Yeon AHN
;
Sunmin KIM
;
Ho Sung LEE
;
In Jae OH
;
Kyu Sik KIM
;
Young Chul KIM
;
Yoo Duk CHOI
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. droij@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Crizotinib;
EML4-ALK fusion protein, human;
Hepatitis
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Hepatitis;
Hepatitis B, Chronic;
Humans;
Lymphoma*
- From:Soonchunhyang Medical Science
2014;20(1):35-38
- CountryRepublic of Korea
- Language:English
-
Abstract:
Crizotinib-associated severe hepatotoxicity has been rarely reported and experts recommended stopping crizotinib treatment in patients with grade 3/4 transaminase elevation. We experienced a case of anaplastic lymphoma kinase-positive non-small cell lung cancer occurring as a result of severe hepatotoxicity due to crizotinib-associated hepatitis, accompanied by the reactivation of chronic hepatitis B, which was reversed with dose reduction and anti-viral therapy. Our case highlights the possibility that crizotinib might induce hepatitis and this might be associated with the underlying presence of chronic hepatitis B. In addition, crizotinib could be continued with reduced unless there are any other therapeutic options.
